Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts

David E. Gerber1, Puja Gupta2, Michael T. Dellinger3,4, Jason E. Toombs3, Michael Peyton4, Inga Duignan5, Jennifer Malaby5, Timothy Bailey5, Colleen Burns5, Rolf A. Brekken3,4, and Nick Loizos5

Abstract

In lung cancer, platelet-derived growth factor receptor α (PDGFRα) is expressed frequently by tumor-associated stromal cells and by cancer cells in a subset of tumors. We sought to determine the effect of targeting stromal PDGFRα preclinically in lung tumor xenograft models (human tumor, mouse stroma). Effects of anti-human (IMC-3G3) and anti-mouse (1E10) PDGFRα monoclonal antibodies (mAb) on proliferation and PDGFRα signaling were evaluated in lung cancer cell lines and mouse fibroblasts. Therapy studies were conducted using established PDGFRα-positive H1703 cells and PDGFRα-negative Calu-6, H1993, and A549 subcutaneous tumors in immunocompromised mice treated with vehicle, anti-PDGFRα mAbs, chemotherapy, or combination therapy. Tumors were analyzed for growth and levels of growth factors. IMC-3G3 inhibited PDGFRα activation and the growth of H1703 cells in vitro and tumor growth in vivo, but had no effect on PDGFRα-negative cell lines or mouse fibroblasts. 1E10 inhibited growth and PDGFRα activation of mouse fibroblasts, but had no effect on human cancer cell lines in vitro. In vivo, 1E10-targeted inhibition of murine PDGFRα reduced tumor growth as single-agent therapy in Calu-6 cells and enhanced the effect of chemotherapy in xenografts derived from A549 cells. We also identified that low expression cancer cell expression of VEGF-A and elevated expression of PDGF-AA were associated with response to stromal PDGFRα targeting. We conclude that stromal PDGFRα inhibition represents a means for enhancing control of lung cancer growth in some cases, independent of tumor cell PDGFRα expression. Mol Cancer Ther; 11(11); 2473–82. ©2012 AACR.

Introduction

Platelet-derived growth factor receptor (PDGFR) is a transmembrane receptor tyrosine kinase. Upon binding of circulating PDGF ligand, PDGFRα and β subunits homodimerize or heterodimerize, undergo autophosphorylation, and activate downstream signal transduction molecules including phosphoinositide 3-kinase, Ras, phospholipase C-γ, Src, and signal transducer and activator of transcription (1). In normal physiology, PDGFRα functions in early and late stages of embryonic development (during which it drives proliferation of undifferentiated mesenchymal populations, tissue remodeling, and cellular differentiation), wound healing, angiogenesis, and modulating interstitial fluid pressure (2, 3).

When expressed on cancer cells, PDGFRα has been implicated in the development and progression of several malignancies (4). Co-expression of PDGF and PDGFRα has been reported in various cancer types, consistent with autocrine-mediated growth (3). In lung cancer, expression of PDGF and/or PDGFRα is associated with more aggressive tumor biology and worse prognosis (5). Specific genetic alterations of the PDGF-PDGFRα axis occur in gastrointestinal stromal tumors (activating mutations in the intracellular domain of PDGFRα; ref. 6), certain gliomas and NSCLCs (PDGFRα amplification; refs. 7, 8), dermatofibrosarcoma protubersans (a 17;22 chromosomal translocation resulting in a fusion oncogene encoding PDGF-B; ref. 9), and hypereosinophilic syndrome (FIP1L1-PDGFRα fusion transcripts; ref. 10).
Given the encouraging results achieved with targeting epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) in patients with lung tumors harboring EGFR mutations and ALK translocations, recent PDGFRA research has focused on identifying those lung cancers with aberrant tumor cell PDGFRA activity as potential candidates for PDGFRA-directed therapy. For instance, in a recent screen of NSCLC cell lines, 1 of 103 cell lines responded in vitro to the PDGF inhibitor sunitinib (11). The sensitive cell line, H1703, was noted to have high-level PDGFRA amplification. Among the larger set of 637 human tumor-derived cell lines evaluated in the study, only one other, the PDGFRA-positive A-204 rhabdomyosarcoma cell line, responded to sunitinib, suggesting that only rare solid tumor patients might benefit from PDGFRA inhibition. However, such an approach does not account for the potential therapeutic effects of stromal PDGFRA inhibition. In tumor stroma, the PDGF–PDGFRα axis functions in fibroblast activation, aberrant epithelial–stromal interactions, modulation of tumor interstitial pressure, and production and secretion of VEGF (12–14). In studies with VEGF-null tumorigenic cells, PDGF-AA was identified as the major stromal fibroblast chemotactic factor produced by the tumor cells that lead to recruitment of VEGF-producing stromal fibroblasts for tumor angiogenesis and growth (14).

To determine the effects of stromal PDGFRA inhibition, we capitalized on xenograft modeling of cancer (human tumor cells, mouse stromal cells) and the availability of species-specific anti-PDGFRA monoclonal antibodies (mAbs). In this model, IMC-3G3, a fully human anti-human PDGFRA mAb, targets tumor cell PDGFRA (15), whereas 1E10, a fully human anti-mouse PDGFRA mAb, targets stromal PDGFRA. Our studies show that targeting stromal PDGFRA has single-agent antitumor activity and the potential to enhance the effect of chemotherapy in murine models of lung cancer. The cell lines of xenografts sensitive to targeting stromal PDGFRA expressed a high PDGF-AA/VEGF-A ratio relative to a resistant xenograft line, thus suggesting a potential selection strategy for therapy.

Materials and Methods

Cell culture

With the exception of A549, which was purchased from the American Type Culture Collection (ATCC), all tumor cell lines were provided by Dr. John Minna (UT Southwestern, Dallas, TX; ref. 16). Cell lines were authenticated. Specifically, the identity of each cell line was confirmed by DNA fingerprinting via short tandem repeats (Promega) and confirmed to be the same as the DNA fingerprint library maintained by ATCC and the Minna/Gazdar lab (the primary source of the lines), and confirmed to be free of mycoplasma by e-Myco kit (Boca Scientific).

Using previously generated genomic microarray data (Affymetrix, Inc. and Illumina, Inc.), 29 NSCLC cell lines with varying expression of PDGFRA were identified. To confirm microarray findings, selected cells were grown in media, harvested at 70% to 80% confluency, and lysates extracted. Equal amounts of protein were subjected to SDS-PAGE followed by Western blot analysis with anti-PDGFRA antibodies and detected by chemiluminescence. In addition, confirmation by quantitative PCR was carried out. RNA was prepared using TRIzol (Invitrogen) according to the manufacturer’s instructions. The quality of RNA was evaluated using spectrophotometry. The cDNA used for subsequent for PCR was made using iScript (Bio-Rad Laboratories). The expression of human PDGFRA was analyzed by quantitative real-time RT-PCR using an assay on demand (Mm00440111_m1) from Applied Biosystems. Mouse GAPDH and human RPLPO (Applied Biosystems assay-on-demand) were used as internal reference genes to normalize input cDNA. Quantitative real-time RT-PCR was carried out in a reaction volume of 25 μL including 5 μL of cDNA, and each reaction was done in triplicate. The comparative Ct method was used to compute relative expression values (17).

Anti-PDGFRA antibody generation and characterization

Anti-mouse PDGFRA antibody 1E10 was obtained by selection of a human naïve display Fab library (18) on recombinant mouse PDGFRA extracellular domain protein following a protocol described previously (19). After being converted into full-length IgG format, 1E10 was expressed in NS0 cells as described (20). Full-length IgG1 antibody was purified by protein A affinity chromatography (Poros A, PerSeptive Biosystems, Inc.). IMC-3G3, a fully human anti-human PDGFRA IgG1 mAb, was developed as reported previously (15).

Antibody species specificity was confirmed in a solid-phase blocking assay and cell-based signaling assays. In the solid-phase blocking assay, antibodies were first mixed with a fixed amount of mouse PDGFRA/Fc (50 ng at 0.5 μg/mL, R&D Systems). The mixture was transferred to 96-well plates precoated with PDGF-AA (100 ng/well), followed by incubation with a goat anti-human Fc antibody-HRP conjugate (Jackson ImmunoResearch). Plates were read at A450 nm using a microplate reader (Molecular Devices).

Growth factor quantitation

Cells were seeded into 100 mm tissue culture dishes and maintained in 15 mL of media for 96 hours at 5% CO2 and 37°C. At the 96-hour time point, cell monolayers were approximately 85% to 90% confluent. The media was collected and spun 3 times at 1,000 × g to remove particulate matter. The concentration of PDGF-AA and VEGF-A
in the media was measured by ELISA (Quantikine kits from R&D systems; cat. # DAA00B and DVE00). The cells in the dishes were washed with PBS, removed by trypsin and counted for normalization of growth factor concentration to cell number.

**Cell-signaling assays**

Receptor and downstream signaling molecule phosphorylation assays were carried out as described (15). Cell lysates were prepared in lysis buffer a (150 mmol/L NaCl, 50 mmol/L Tris pH 7.4, 1% Triton X-100, 1 mmol/L EDTA, 10 mmol/L NaPPi, 50 mmol/L NaF, 1 mmol/L Na2VO4) with protease inhibitors (Roche, cat. no. 04 693 124 001) and PhosSTOP phosphatase inhibitor (Roche, cat. no. 04 906 845 001). Lysates were separated by SDS-PAGE and transferred to PVDF membranes. Membranes were probed with the following antibodies: anti-PDGFRα (Cell Signaling Technology, #3174), anti-PDGFRβ (Neomarkers, RB-9027), phospho-PDGFRα (Santa Cruz Biotechnology, sc-12910), anti-β-actin (Santa Cruz, sc-8432), anti-phospho-PLCy (Cell Signaling Technology, #2821), anti-PARP (Cell Signaling, #9542), and anti-PDGF-C (Santa Cruz Biotechnology, sc-18228). Antibody reactivity was detected using the appropriate peroxidase conjugated secondary antibody (Jackson ImmunoResearch) and subsequent chemiluminescence substrate (Pierce).

**MTS assay**

Cells were carried out as described previously (21). In brief, 500 to 4,000 cells were allowed to seed for 24 hours before 4-fold serial dilutions of drug were added. The maximum dose was 500 μg/mL (~3,300 nmol/L) for IMC-3G3 and 1E10. Cells were incubated for 4 days then relative cell number was determined by the addition of MTS (Promega, final concentration 333 μg/mL), incubating for 1 to 3 hours at 37°C and reading absorbance at 490 nm in a plate reader (Spectra Max 190, Molecular Devices). Each experiment contained 8 replicates per concentration and the entire assay was carried out in multiple replicates. Drug sensitivity curves and IC50 values were calculated using in-house software (DIVISA).

**Animal studies**

Animal studies were conducted according to U.S. Department of Agriculture and NIH guidelines and approved by the respective Institutional Animal Care and Use Committees. Female athymic nude (Crl:NU/ NU-nuBR, Charles River Laboratories) or SCID mice were implanted subcutaneously with 5 to 20 × 106 cells from selected NSCLC cell lines, as previously described (15). For the H1703 monotherapy study, mice were randomized into 2 groups (n = 12) and treated with human IgG (40 mg/kg) or IMC-3G3 (40 mg/kg) 3 times weekly. There is a precedent in animal studies for antibody treatment at 40 mg/kg to achieve circulating antibody trough levels consistent with those achieved in man. For example, the target serum concentration for IMC-3G3 is hypothesized to be one that maintains concentrations above levels associated with inhibition of the growth of human tumor growth xenograft models in mice (155 to 258 μg/mL). Results of the PK data from patients in the IMC-3G3 phase 1 study show that IMC-3G3 dosing yielded serum concentrations at or above the target trough concentrations (22).

In the 1E10 plus chemotherapy combination studies in A549 and H1993 xenografts, cohorts of animals with established tumors were randomized into 4 groups (n = 8) and treated with (1) vehicle, (2) chemotherapy (cisplatin, 1 mg/kg 1×/week; gemcitabine 25 mg/kg, 2×/week), (3) 1E10, or (4) chemotherapy plus 1E10. Mice were treated by i.p. injection twice weekly for the duration of the study. In each group, on the day of dosing, the first treatment listed above was administered first, followed by the second treatment 30 minutes later. Tumor volumes were evaluated twice weekly. In all xenograft studies, animals were assessed for toxicity (weight loss, death, cage side observations) and tumors were measured twice weekly. Tumor volume was calculated according to the formula π/6 × longest length × perpendicular width2. Tumor growth in the treatment groups was compared with a repeated-measures ANOVA.

Tumors were harvested for analysis of growth factors by ELISA and Western blotting. Tumors were homogenized in lysis buffer b (Cell Signaling, cat. no. 9803) supplemented with protease inhibitors (Roche) and Phos-Stop phosphatase inhibitor (Roche). The lysates were centrifuged twice at 14,000 rpm and the protein concentration for the collected supernatant was determined (Bio-Rad, cat. no. 500-0116).

**Statistical analysis**

For cell proliferation assays, sigmoidal dose response curves were fitted and the inhibitory concentrations at 50% (IC50) were calculated using the Weibull model. Tumor volumes and weights were compared using the Student t test. For IHC studies, tumors were analyzed and compared by one-way ANOVA, followed by Fisher LSD Post hoc test for multiple comparisons. The number of samples in each group was always taken as the number of tissues used in the analysis. For PDGF-CC analysis, Adobe Photoshop 7 was used to determine the mean luminosity of the Western blotting protein bands. The mean luminosity of each PDGF-C GFD band was normalized by the mean luminosity of the respective β-actin band. These values were plotted in GraphPad Prism 5, and an unpaired t test was used to determine significance. All calculated P values are 2 sided. For all tests, P < 0.05 was considered significant.

**Results**

**NSCLC cell line PDGFRα expression and response to inhibition**

PDGFRα expression was evaluated by microarray analysis in a panel of NSCLC cell lines (n = 119; Fig. 1a). A subset of these lines (n = 32) were screened...
for protein expression by Western blot analysis (Supplementary Fig. S1). PDGFRα expression was shown in human H1703 NSCLC cells, but not in A549 or H1993 cells or in mouse fibroblasts (3T3 cells and MEFs; Fig. 1b). Twenty-nine NSCLC cell lines with varying PDGFRα expression by microarray analysis were selected and treated in vitro with escalating concentrations of IMC-3G3. A single cell line, H1703, expressed PDGFRα robustly at the protein level and showed sensitivity to IMC-3G3 with an IC₅₀ of 225 nmol/L (34 μg/mL). All other cell lines (including A549, H1993, and Calu-6) showed resistance to IMC-3G3, with IC₅₀ greater than 3,300 nmol/L (500 μg/mL; see Table 1). The PDGFRα-positive H1703 lung cancer line contains both PDGFRα and PDGF-CC gene amplifications and shows a codependence on this axis for proliferation (11). Codependency of this kind is a rare event in human lung cancer cell lines, suggesting that only a limited number of lung tumor patients might benefit from tumor cell PDGFRα inhibition. In contrast, IMC-3G3 did not inhibit proliferation of H1792 cells (IC₅₀ > 500 μg/mL). These cells overexpress PDGFRα (see Supplementary Fig. S1) but not PDGF ligand (11). This observation suggests that, in the absence of PDGFRα mutation or amplification, overexpression of both ligand and receptor are required for cell autonomous growth.

Characterization of IMC-3G3 and 1E10

We capitalized on the xenograft model (human cancer cells, mouse stromal cells) and species-specific mAbs to evaluate the effects of inhibiting tumor cell and stromal PDGFRα. Species-specific targeting was showed through binding assays, Western blot analysis, and effects on receptor activation and signaling. The anti-human PDGFRα mAb IMC-3G3 has been previously described (15). To target stromal PDGFRα, an anti-mouse PDGFRα mAb (1E10) was generated. 1E10 was shown to inhibit PDGF-AA from binding to murine PDGFRα with an IC₅₀ of 8.51 × 10⁻⁹ M (Fig. 2a). IMC-3G3 had no blocking effect in this assay. Antibody 1E10 showed immunoreactivity with PDGFRα-positive mouse fibroblasts but not with PDGFRα-positive human H1703 NSCLC cells (Supplementary Fig. S2). Conversely, IMC-3G3 had immunoreactivity with PDGFRα-positive human H1703 NSCLC cells but not with PDGFRα-positive mouse fibroblasts or with PDGFRα-negative human A549 NSCLC cells (Supplementary Fig. S2). Therefore, the use of IMC-3G3 in subcutaneous human xenograft models using tumors lines that are PDGFRα-negative would be ineffective and would not discern the therapeutic effects of stromal PDGFRα inhibition. PDGFAA-mediated phosphorylation of PDGFRα and PLCγ in H1703 cells was inhibited by IMC-3G3 but...
not by 1E10 (Fig. 2b). In contrast, 1E10 but not IMC-3G3 inhibited activation of PDGFRα and the signal transduction mediator PLCγ in PDGF-stimulated mouse fibroblasts in vitro (Fig. 2c). 1E10 inhibited PDGF-AA-induced phosphorylation of mouse PDGFRα but not PDGF-BB-induced phosphorylation of mouse PDGFRβ (Fig. 2d).

### Table 1. Expression of PDGF-AA and VEGF-A and response to PDGFRα inhibition in lung cancer cell lines grown in culture and in vivo

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Avg PDGF-AA (ng/mL/10⁶ cells ± SD)</th>
<th>Avg VEGF-A (ng/mL/10⁶ cells ± SD)</th>
<th>Ratio PDGF-AA/VEGF-A</th>
<th>Ratio VEGF-A/PDGFR AA</th>
<th>In vitro anti-human PDGFRα mAb IC₅₀ (μg/mL)</th>
<th>In vivo anti-mouse PDGFRα mAb tumor/control volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calu-6</td>
<td>0.0708 ± 0.0350</td>
<td>0.1388 ± 0.0769</td>
<td>0.51</td>
<td>1.960</td>
<td>&gt;500</td>
<td>0.51</td>
</tr>
<tr>
<td>A549</td>
<td>0.0783 ± 0.0232</td>
<td>0.8518 ± 0.255</td>
<td>0.092</td>
<td>10.874</td>
<td>&gt;500</td>
<td>0.66</td>
</tr>
<tr>
<td>H1993</td>
<td>0.0235 ± 0.0148</td>
<td>1.5476 ± 0.178</td>
<td>0.015</td>
<td>65.855</td>
<td>&gt;500</td>
<td>1.21</td>
</tr>
<tr>
<td>H2073</td>
<td>0.0086 ± 0.0010</td>
<td>0.5224 ± 0.131</td>
<td>0.016</td>
<td>60.742</td>
<td>&gt;500</td>
<td>N/A</td>
</tr>
<tr>
<td>H1703</td>
<td>Bld</td>
<td>2.0254 ± 0.0784</td>
<td>N/A</td>
<td>N/A</td>
<td>34</td>
<td>N/A</td>
</tr>
</tbody>
</table>

NOTE: Cells were grown for 96 hours at 37°C and 5% CO₂. Supernatants were collected and analyzed by ELISAs to quantitate secreted VEGF-A and PDGFR-AA.

Abbreviations: Bld, below limits of detection; N/A, not applicable; SD, standard deviation.

*With the exception of H1703, all tested NSCLC cell lines (N = 29) were resistant to anti-PDGFRα antibody therapy in vitro (IC₅₀ > 500 μg/mL).

*Extrapolated values.

Figure 2. Species-specific activity of IMC-3G3 and 1E10. A, inhibition of mouse PDGFRα binding to immobilized PDGF-AA by 1E10 but not IMC-3G3. Antibodies were preincubated with a fixed amount of Fc-tagged-mouse PDGFRα and then this mixture was transferred to a plate precoated with PDGF-AA. Plate-bound mouse PDGFRα was detected with a goat-anti-human Fc antibody-HRP conjugate. B, PDGF-AA-mediated phosphorylation of PDGFRα and PLCγ in H1703 cells is inhibited by IMC-1E10 but not by 3G3. H1703 cells were nonstimulated (NS) or stimulated with PDGF-AA and PDGF-BB (5 nmol/L) for 5 minutes and treated with antibodies. 1E10 and IMC-3G3 were used at concentrations of 132 μg/mL (880 nmol/L) and 50 ng/mL (1.7 nmol/L) for 5 minutes after incubation and probed by Western blotting for the targets indicated. C, in vitro activity of 1E10 in mouse fibroblasts. PDGF-AA-mediated phosphorylation of PDGFRα and PLCγ in mouse fibroblasts is inhibited by IMC-1E10 but not by 3G3. Mouse fibroblasts were nonstimulated (NS) or stimulated with PDGF-AA and treated with antibodies. Lysates were prepared 10 minutes after incubation and probed by Western blotting for the targets indicated. D, specific inhibition of mouse PDGFRα phosphorylation by 1E10. NIH3T3 mouse fibroblasts were rendered quiescent, treated with mAbs, and then stimulated with either PDGF-AA or PDGF-BB. Afterward, cell lysates were analyzed by SDS-PAGE and Western blotting with an antiphosphotyrosine antibody. 1E10 inhibited PDGF-AA-induced phosphorylation of PDGFRα but not PDGF-BB-induced phosphorylation of PDGFRβ.
In vitro and in vivo activity of IMC-3G3 on PDGFRα–positive NSCLC

In vitro, human H1703 cells were sensitive to IMC-3G3 in MTS assay (IC₅₀ = 10 μg/mL), but were resistant to 1E10 (IC₅₀ > 1,000 μg/mL; Fig. 3a). In addition, IMC-3G3 significantly inhibited growth of H1703 xenografts (P = 0.0003, Fig. 3b). Tumors in mice receiving IMC-3G3 (mean final volume 433 ± 18 mm³) were significantly smaller than in mice receiving control IgG (mean final volume 1,233 ± 211 mm³), corresponding to a 65% reduction in final tumor volume.

In vivo antitumor activity of 1E10 on PDGFRα-negative xenografts with high PDGF-AA/VEGF-A ratio

Given that PDGF-AA has been identified as a major stromal fibroblast chemotactic factor produced by tumor cells (14), it may be assumed that xenograft lines that express high PDGF-AA would have a greater dependence on stromal activation for growth. Therefore, 13 lung cancer cell lines were screened for PDGF-AA expression to identify lines for in vivo antitumor studies targeting stromal PDGFRα. Specifically, the cell lines were grown in vitro and expressed PDGF-AA was measured from the supernatants (Table 1). Two lines expressing the highest PDGF-AA were chosen for in vitro therapeutic studies of 1E10. In A549 and Calu-6 xenografts, 1E10 treatment attenuated tumor growth, showing a significant therapeutic effect of stromal targeting (Fig. 4). In Calu-6 xenografts, average tumor size on Day 32 was 1,273 ± 187 mm³ with 1E10 treatment, compared with 2,483 ± 302 mm³ with control IgG (P = 0.002; Fig. 4a). In A549 xenografts, average tumor size on Day 36 was 632 ± 65 mm³ with 1E10 treatment, compared with 960 ± 93 mm³ with control IgG (P = 0.01; Fig. 4b). 1E10 also enhanced the effect of cisplatin-gemcitabine chemotherapy in A549 xenografts (Fig. 4c). Final tumor weights were as follows: control IgG 1.05 ± 0.20 g, 1E10 0.74 ± 0.08 g, cisplatin-gemcitabine 0.91 ± 0.15 g, cisplatin-gemcitabine plus 1E10 1.05 ± 0.05 g (P = 0.04 for cisplatin-gemcitabine plus 1E10 compared with cisplatin-gemcitabine). Of note, these sensitive cell lines had relatively low in vitro expression of VEGF-A compared with PDGF-AA (VEGF-A/PDGF-AA ratio 1.96 in Calu-6 cells and 10.87 in A549 cells; Table 1).

Targeting of stromal PDGFRα with 1E10 had no activity as a monotherapy on the H1993 xenograft (Fig. 4d). In addition, 1E10 did not enhance the effect of cisplatin-gemcitabine chemotherapy in H1993 xenografts (final weights: control IgG 0.79 ± 0.09 g, 1E10 0.78 ± 0.06 g, cisplatin-gemcitabine 0.28 ± 0.05 g, cisplatin-gemcitabine plus 1E10 0.26 ± 0.07 g; Fig. 4d). This cell line resistant to stromal PDGFRα inhibition had an elevated VEGF-A/PDGF-AA ratio of 65.86 (Table 1). Also of note, in the H1993 xenografts, chemotherapy alone inhibited tumor growth, but A549 xenografts were resistant to the same regimen.

Discussion

High-throughput in vitro screens offer a means to test antitumor agents against multiple cancer cell lines relatively quickly and inexpensive. Although such features have rendered this a preferred approach to early-stage preclinical drug development, these studies provide no insight into tumor stromal effects. For inhibitors of PDGFRα, a target expressed on cancer cells and stromal fibroblasts, in vivo testing would facilitate showing the full spectrum of therapeutic effects. In agreement with previous studies (11), this report shows that, in vitro, PDGFRα-directed therapy has efficacy in a small proportion of cell lines with PDGFRα overexpression.

However, in addition, stromal PDGFRα targeting in vivo reduced tumor growth and enhanced the effect of cytotoxic chemotherapy for 2 xenografts, independent of tumor cell PDGFRα expression. The results are consistent with paracrine effects of the PDGF-PDGFRα axis, in which stromal fibroblasts express PDGFRα and malignant cells secrete PDGFs (23, 24). These results echo those of earlier reports suggesting that therapeutic stromal effects, which become apparent in animal models, might otherwise go unrecognized in cell culture assays (25, 26).

Potential explanations for the therapeutic outcome of stromal-PDGFR targeting include effects on fibroblast...
activation and angiogenesis (12, 14, 27). In a previous report, PDGF-AA, which binds PDGFRα but not PDGFRβ, was shown to be the major stromal fibroblast chemotactic factor produced by VEGF-null tumorigenic cells (14). In that system it was concluded that PDGFRα signaling is required for the recruitment of VEGF-producing stromal fibroblasts for tumor angiogenesis and growth. In the present study, tumor cell PDGF-AA and VEGF expression levels suggested an explanation as to why only certain lines responded to stromal PDGFRα inhibition. Elevated cancer cell expression of PDGF-AA and low expression of VEGF were associated with response to stromal PDGFRα targeting. Specifically, sensitive cell lines had relatively low VEGF-A expression (VEGF-A/PDGF-AA ratio 1.96 in Calu-6 cells and 10.87 in A549 cells), whereas the resistant cell line H1993 had elevated VEGF-A (VEGF-A/PDGF-AA ratio 65.86) when grown in cell culture. This difference may suggest that the 1E10-sensitive tumors have a relatively greater dependence on PDGF-AA-induced production of stromal VEGF. Notably, we have previously showed the converse for anti-VEGF monoclonal antibody (bevacizumab) sensitivity, with H1993 xenografts responding to therapy but A549 and Calu-6 exhibiting a poor response (28). If the predictive value of PDGF-AA/VEGF ratio is confirmed preclinically, it would be reasonable to test this biomarker in the clinical setting.

Potential explanations for the effects of stromal PDGFR targeting include effects on angiogenesis, fibroblast activation, and tumor interstitial pressure (12). Preclinical studies have showed that imatinib, a multiltargeted tyrosine kinase inhibitor that inhibits PDGFR, reduces interstitial fluid pressure and increases intratumoral concentration of concurrently administered cytotoxic chemotherapy (29, 30). That 1E10 significantly improved the effect of cisplatin–gemcitabine in the A549 xenografts might suggest reduction of tumor interstitial pressure and enhanced chemotherapy delivery. PDGF-activated stromal fibroblasts synthesize collagen, express matrix metalloproteinases, and form a connective tissue network, all of which promote tumor development (31–33). Although the present experiments do not elucidate a therapeutic mechanism of stromal PDGFRα inhibition, it is unlikely that the observed in vivo effects represent a nonstromal mechanism. The possibility that stromal PDGFRα inhibition has distinct antiangiogenic effects that are not shared by anti-VEGF targeting suggests that targeting stromal PDGFRα may have advantages over anti-VEGF therapy in some cancers.
that PDGFRA-negative cell lines adapt to express PDGFRA in vivo was considered. However, no human PDGFRA was detected in tumor lysates, and the anti-human PDGFRA antibody IMC-3G3 had no effect on A549 xenograft tumor growth (data not shown).

Although a number of PDGFR inhibitors are currently FDA-approved for cancer treatment, these drugs are all relatively nonspecific small molecule kinase inhibitors. This lack of specificity has therapeutic as well as experimental consequences. For instance, due to cross-reactivity with c-KIT, imatinib is associated with hematologic toxicity precluding its concomitant administration with cytotoxic chemotherapy (12). PDGFR kinase inhibitors also inhibit both PDGFR subunits. Inhibition of PDGFRα, which is expressed predominantly on vessel pericytes and modulates vascular permeability, may result in clinically significant fluid retention, pleural, and pericardial effusions, peripheral edema, and weight gain (34). In contrast, the role of PDGFRα in normal adult physiology appears limited to wound healing (3). Consequently, PDGFRα may be a less toxic and more therapeutically potent target. In a recently completed phase I monotherapy study, no specific adverse events were consistently or conclusively associated with IMC-3G3 (22, 35). Importantly, it has been noted that in cancer cells expressing both PDGF and PDGFR, PDGF forms a complex with PDGFR within the endoplasmic reticulum (36), an intracellular sanctuary site not available to antibody-based therapeutics. However, the PDGF-PDGFR complex generates mitogenic signals only after migration to the cell membrane, where it is accessible to neutralizing antibodies (37).

Partly for reasons described above, clinical trials of PDGFR inhibitors combined with chemotherapy for lung cancer therapy have been negative to date, and some have showed a substantial increase in toxicity (38, 39). However, the results seen with tyrosine kinase inhibitors targeting PDGFR cannot be extrapolated to a highly specific monoclonal antibody such as IMC-3G3. With EGFR inhibitors and antiangiogenic agents, no benefit was seen when tyrosine kinase inhibitors were combined with chemotherapy, but the addition of a monoclonal antibody such as IMC-3G3. With EGFR inhibitors and antiangiogenic agents, no benefit was seen when tyrosine kinase inhibitors were combined with chemotherapy, but the addition of a monoclonal antibody to chemotherapy improved overall survival (40–44).

The implication that stromal PDGFR targeting could add benefit to NSCLC therapy is substantial. The overwhelming majority of NSCLCs feature stromal PDGFR expression (5, 45, 46). Our findings support the possibility that the therapeutic effects of stromal PDGFRα inhibition may reach beyond the rare cancers sensitive to cancer-cell PDGFRα targeting. In general, stromal targets have a number of favorable properties. They are less prone to mutation than are cancer cell targets. As shown by the broad clinical use of anti-VEGF antibodies, stromal targeting may be relevant to multiple cancer types. Finally, stromal-directed therapies have been combined effectively and safely with cancer cell-directed treatments, including cytotoxic chemotherapy. As shown in our experiments, for those cancers without tumor cell PDGFRα expression, an anti-PDGFRα antibody may be most effective when combined with conventional chemotherapy or other targeted agents. Accordingly, the results of ongoing phase 2 trials incorporating anti-PDGFRα mAbs into combination therapy for various malignancies are awaited to evaluate this strategy in the clinical setting.

Disclosure of Potential Conflicts of Interest
D.E. Gerber and R.A. Brekken receive research funding from ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, New York, NY. I. Duignan, J. Malaby, T. Bailey, C. Burns, and N. Loizos are employed by ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, New York, NY.

Authors’ Contributions
Conception and design: D.E. Gerber, Puja Gupta, M. Peyton, R.A. Brekken, N. Loizos
Development of methodology: D.E. Gerber, Puja Gupta, M. Peyton, T. Bailey, C. Burns
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): D.E. Gerber, Puja Gupta, M.T. Delinger, J.E. Toombs, M. Peyton, I. Duignan, J. Malaby, C. Burns, N. Loizos
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): D.E. Gerber, Puja Gupta, M. Peyton, I. Duignan, J. Malaby, C. Burns, R.A. Brekken, N. Loizos
Writing, review, and/or revision of the manuscript: D.E. Gerber, M. Peyton, J. Malaby, C. Burns, R.A. Brekken, N. Loizos
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): D.E. Gerber, R.A. Brekken
Study supervision: D.E. Gerber, R.A. Brekken, N. Loizos

Acknowledgments
The authors acknowledge the assistance of the Biostatistics and Microarray Shared Resources at the Harold C. Simmons Cancer Center, which is supported in part by a National Cancer Institute Cancer Center Support Grant, P30 CA142543-01, and the support of Drs. John Minna and Joan Schiller. The authors thank Ilse Valencia for assistance with PDGFRα Western blot analysis and PCR in NSCLC cell lines and immortalized human bronchial epithelial cells. The authors also thank Marie Prewett for help with statistical calculations.

Grant Support
Supported by a National Institutes of Health UL1 RR024982 and KL2 RR024958-03 "North and Central Texas Clinical and Translational Science Initiative (NCTCTSI)” grants (D.E. Gerber), a sponsored research agreement from Imclone Systems (D.E. Gerber and R.A. Brekken) and The Effie Marie Cain Scholarship in Angiogenesis Research (R.A. Brekken). P. Gupta was supported by NCI training grant T32CA098640.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 1, 2012; revised July 5, 2012; accepted July 30, 2012; published OnlineFirst August 28, 2012.

References
Stromal PDGFRα Targeting in Lung Cancer


Stromal Platelet-Derived Growth Factor Receptor \(\alpha\) (PDGFR\(\alpha\)) Provides a Therapeutic Target Independent of Tumor Cell PDGFR \(\alpha\) Expression in Lung Cancer Xenografts

David E. Gerber, Puja Gupta, Michael T. Dellinger, et al.


Updated version  Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-12-0431

Supplementary Material  Access the most recent supplemental material at: http://mct.aacrjournals.org/content/suppl/2012/08/28/1535-7163.MCT-12-0431.DC1

Cited articles  This article cites 44 articles, 21 of which you can access for free at: http://mct.aacrjournals.org/content/11/11/2473.full.html#ref-list-1

Citing articles  This article has been cited by 3 HighWire-hosted articles. Access the articles at: /content/11/11/2473.full.html#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.